Abstract
IgA vasculitis is a form of cutaneous small-vessel leukocytoclastic vasculitis (LCV) that has various triggers, including anti-tumor necrosis factor (TNF) α therapy. As the use of more targeted biologic therapies such as the IL-17 inhibitor secukinumab increases, so do reports of associated adverse events. Herein, we describe an uncommon case of IgA vasculitis in a man undergoing biologic therapy with adalimumab and secukinumab for psoriasis with recurrent cutaneous methicillin-resistant Staphylococcus aureus (MRSA) colonization. A review of the current literature also is provided.
Original language | English |
---|---|
Pages (from-to) | E4-E10 |
Journal | Cutis |
Volume | 110 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2022 |
Externally published | Yes |